← Back to Search

Mitochondrial Targeted Antioxidant

MitoQ for Chronic Kidney Disease

N/A
Waitlist Available
Led By Danielle L Kirkman, PhD
Research Sponsored by Virginia Commonwealth University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change over 4 weeks
Awards & highlights

Study Summary

This trial looks at how well exercise capacity and blood flow in the arteries is in people with heart failure and kidney disease, compared to those with just heart failure.

Eligible Conditions
  • Chronic Kidney Disease
  • Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change over 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change over 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Exercise Capacity
Secondary outcome measures
Forward Pulse Wave Amplitude
Mitochondrial Respiration
Reflected Pulse Wave Amplitude

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MitoQExperimental Treatment1 Intervention
20mg daily oral dose of MitoQ
Group II: PlaceboPlacebo Group1 Intervention
Oral TTP placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MitoQ
2006
Completed Phase 2
~230

Find a Location

Who is running the clinical trial?

Virginia Commonwealth UniversityLead Sponsor
698 Previous Clinical Trials
22,884,970 Total Patients Enrolled
Danielle L Kirkman, PhDPrincipal InvestigatorVirginia Commonwealth University
1 Previous Clinical Trials
24 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial Dysfunction
2019. "Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial Dysfunction". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03960073.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top